Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021
08 Novembro 2021 - 10:00AM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces that it will
release financial results for the three and nine months ended
September 30, 2021 after the market closes on Monday, November 15,
2021. The Company will host an investor conference call to discuss
the results and answer questions at 4:30 p.m. Eastern time (1:30
p.m. Pacific time).
Date/Time:
Monday, November 15, 4:30 p.m. ET / 1:30
p.m. PT
Pre-Registration:
Participants can pre-register for the
conference call here.
Callers who pre-register will be given a
conference passcode and unique PIN to gain immediate access to the
call and bypass the live operator. Participants may pre-register at
any time, including up to and after the call start time.
Dial In:
Those who choose not to pre-register can
access the live conference call by dialing the following and
requesting the Biocept call:
U.S. Callers:
855-656-0927
Canadian Callers:
855-669-9657
Other International Callers:
412-902-4109
A live webcast of the call will be available at
https://ir.biocept.com/. The webcast will be archived for 90
days.
A replay of the conference call will be available for 48 hours
following the conclusion of the call by dialing (877) 344-7529 for
domestic callers, (855) 669-9658 for Canadian callers, or (412)
317-0088 for other international callers, and entering the replay
access code 10161580.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept has developed the CNSide™
cerebrospinal fluid assay that detects cancer that has metastasized
to the central nervous system. Biocept’s patented Target Selector™
technology captures and quantitatively analyzes CSF tumor cells for
tumor-associated molecular markers, using technology first
developed for use in blood. Biocept also is leveraging its
molecular diagnostic capabilities to offer nationwide COVID-19
RT-PCR testing to support public health efforts during this
unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211108005056/en/
LHA Investor Relations Jody Cain Jcain@lhai.com
310-691-7100
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024